Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

(2022) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

(2021) Frederik Marmé et al.   JOURNAL OF CLINICAL ONCOLOGY

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

(2021) A. Gennari et al.   ANNALS OF ONCOLOGY

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

(2020) Richard S. Finn et al.   BREAST CANCER RESEARCH AND TREATMENT

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

(2020) K. Kalinsky et al.   ANNALS OF ONCOLOGY

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

(2019) Peng Yuan et al.   EUROPEAN JOURNAL OF CANCER

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

(2019) George W. Sledge et al.   JAMA Oncology

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

(2019) M.E. Cazzaniga et al.   BREAST

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

(2019) Jennifer J Gao et al.   LANCET ONCOLOGY

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

(2019) Dennis J. Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

(2016) X. Pivot et al.   ANNALS OF ONCOLOGY

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2015) Peter A. Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trop-2 Is a Determinant of Breast Cancer Survival

(2014) Federico Ambrogi et al.   PLoS One

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER